Creutzfeldt-Jakob Disease F005
Current RMA Instruments
| Reasonable Hypothesis SOP [1] | 76 of 2014 |
| Balance of Probabilities SOP [2] | 77 of 2014 |
Changes from previous Instruments
SOP Bulletin 177 [3]
ICD Coding
- ICD-9-CM Codes: 046.1
- ICD-10-AM Codes: A81.0
Brief description
This SOP covers both Creutzfeldt-Jakob disease (CJD), a rapidly progressive degenerative brain disorder, and variant CJD associated with mad cow disease. CJD is a very rare disease. No case of variant CJD has ever been reported in Australia (at Feb ‘21).
Confirming the diagnosis
This diagnosis is complex and requires diagnosis by a specialist neurologist or infectious disease physician, or confirmation by autopsy.
Additional diagnoses covered by SOP
- Classical Creutzfeldt Jakob disease
- Variant Creutzfeldt Jakob disease
Conditions excluded from SOP
- Kuru - non SOP
- Other forms of dementia
Clinical onset
Mean age of onset is around 60. The typical clinical presentation is with rapid neuropsychiatric decline.
Clinical worsening
There are no clinical worsening factors in the SOP.
Rulebase for Creutzfeldt-Jakob disease
- Log in [4] to post comments
Place holder node for Rulebase for Creutzfeldt-Jakob disease
Dura mater graft
Creutzfeldt-Jakob disease - Dura mater graft Factor
Last reviewed for CCPS 15 May 1998.
Preliminary questions [16286]
16375 [5] there is some evidence that undergoing a dura mater graft may be a factor in the development of the condition under consideration.
16313 [5] the veteran has undergone a dura mater graft at some time. the veteran has undergone a dura mater graft before the clinical onset of Creutzfeldt-Jakob disease. 16316 — the veteran has established the causal connection between the dura mater graft and VEA service for Creutzfeldt-Jakob disease. 16317 — the veteran has established the causal connection between the identified illness or injury for which the dura mater graft was given and operational service for the clinical onset of Creutzfeldt-Jakob disease. or 16318 — the veteran has established the causal connection between the identified illness or injury for which the dura mater graft was given and eligible service for the clinical onset of Creutzfeldt-Jakob disease. Clinical onset and operational service [16317]
or
16315 — the dura mater graft was given for an illness or injury which is identifiable. [9]
16319 — the identified illness or injury for which the dura mater graft is causally related to operational service. [10] [11]
Clinical onset and eligible service [16318]
16315 — the dura mater graft was given for an illness or injury which is identifiable. [9]
16320 — the identified illness or injury for which the dura mater graft is causally related to eligible service. [12] [11]
Surgery to the central nervous system or cornea
Creutzfeldt-Jakob disease - Surgery to the central nervous system or cornea Factor
Last reviewed for CCPS 15 May 1998.
Preliminary questions [16285]
16305 [13] the veteran has had surgery to the central nervous system or cornea at some time. the veteran had surgery to the central nervous system or cornea before the clinical onset of Creutzfeldt-Jakob disease. 16308 — the veteran has established the causal connection between the surgery to the central nervous system or cornea and VEA service for Creutzfeldt-Jakob disease. 16309 — the veteran has established the causal connection between the surgery to the central nervous system or cornea and operational service for the clinical onset of Creutzfeldt-Jakob disease. or 16310 — the veteran has established the causal connection between the surgery to the central nervous system or cornea and eligible service for the clinical onset of Creutzfeldt-Jakob disease. Clinical onset and operational service [16309] or 16311 — the identified illness or injury for which the surgery to the central nervous system or cornea was given is causally related to operational service. [17] [18] Clinical onset and eligible service [16310]
16312 — the identified illness or injury for which the surgery to the central nervous system or cornea was given is causally related to eligible service. [20] [18]
Treatment with human pituitary gonadotrophins
Creutzfeldt-Jakob disease - Treatment with human pituitary gonadotrophins Factor
Last reviewed for CCPS 15 May 1998.
Preliminary questions [16284]
16374 [21] there is some evidence that treatment with human pituitary gonadotrophins may be a factor in the development of the condition under consideration.
1169 — the veteran is a woman. [22] the veteran has had treatment with human pituitary gonadotrophins at some time. the veteran had treatment with human pituitary gonadotrophins before the clinical onset of Creutzfeldt-Jakob disease. 16300 — the veteran has established the causal connection between the treatment with human pituitary gonadotrophins and VEA service for Creutzfeldt-Jakob disease. 16301 — the veteran has established the causal connection between the treatment with human pituitary gonadotrophins and operational service for the clinical onset of Creutzfeldt-Jakob disease. or 16302 — the veteran has established the causal connection between the treatment with human pituitary gonadotrophins and eligible service for the clinical onset of Creutzfeldt-Jakob disease. Clinical onset and operational service [16301] or 16303 — the identified illness or injury for which treatment with human pituitary gonadotrophins was given is causally related to operational service. [26] [27] Clinical onset and eligible service [16302]
16304 — the identified illness or injury for which treatment with human pituitary gonadotrophins was given is causally related to eligible service. [29] [27]
Treatment with human pituitary growth hormone
Creutzfeldt-Jakob disease - Treatment with human pituitary growth hormone Factor
Last reviewed for CCPS 15 May 1998.
Preliminary questions [16283]
16373 [30] there is some evidence that treatment with human pituitary growth hormone may be a factor in the development of the condition under consideration.
16287 [30] the veteran has had treatment with human pituitary growth hormone at some time. the veteran had treatment with human pituitary growth hormone before the clinical onset of Creutzfeldt-Jakob disease. 16289 — the veteran has established the causal connection between the treatment with human pituitary growth hormone and VEA service for Creutzfeldt-Jakob disease. 16292 — the veteran has established the causal connection between the treatment with human pituitary growth hormone and operational service for the clinical onset of Creutzfeldt-Jakob disease. or 16293 — the veteran has established the causal connection between the treatment with human pituitary growth hormone and eligible service for the clinical onset of Creutzfeldt-Jakob disease. Clinical onset and operational service [16292] or 16295 — the identified illness or injury for which treatment with human pituitary growth hormone was given is causally related to operational service. [34] [35] Clinical onset and eligible service [16293]
16296 — the identified illness or injury for which treatment with human pituitary growth hormone was given is causally related to eligible service. [37] [35]
Links
[1] http://www.rma.gov.au/assets/SOP/2014/076.pdf
[2] http://www.rma.gov.au/assets/SOP/2014/077.pdf
[3] https://clik.dva.gov.au/system/files/media/Bull177_5.pdf
[4] https://clik.dva.gov.au/user/login?destination=comment/reply/63446%23comment-form
[5] https://clik.dva.gov.au/ccpsf005rc-1
[6] clikpopup://CCPS/reject16313No
[7] clikpopup://CCPS/reject16314No
[8] clikpopup://CCPS/reject24916No
[9] clikpopup://CCPS/reject16315No
[10] clikpopup://CCPS/reject16319No
[11] clikpopup://CCPS/reject16319,16320No
[12] clikpopup://CCPS/reject16320No
[13] clikpopup://CCPS/Surgery to central nervous system or cornea at some time
[14] clikpopup://CCPS/reject16305No
[15] clikpopup://CCPS/reject16306No
[16] clikpopup://CCPS/reject24915No
[17] clikpopup://CCPS/reject16307No
[18] clikpopup://CCPS/reject16311,16312No
[19] clikpopup://CCPS/Surgery to central nervous system or cornea before CJD onset for illness
[20] clikpopup://CCPS/reject16312No
[21] https://clik.dva.gov.au/ccpsf005rc-11
[22] clikpopup://CCPS/reject1169No
[23] clikpopup://CCPS/reject16297No
[24] clikpopup://CCPS/reject16298No
[25] clikpopup://CCPS/reject24914No
[26] clikpopup://CCPS/reject16299No
[27] clikpopup://CCPS/reject16303,16304No
[28] clikpopup://CCPS/Treatment with human gonadotrophins before CJD onset for illness
[29] clikpopup://CCPS/reject16304No
[30] https://clik.dva.gov.au/ccpsf005rc-6
[31] clikpopup://CCPS/reject16287No
[32] clikpopup://CCPS/reject16288No
[33] clikpopup://CCPS/reject24913No
[34] clikpopup://CCPS/reject16294No
[35] clikpopup://CCPS/reject16295,16296No
[36] clikpopup://CCPS/Treatment with human growth hormone before CJD onset for illness
[37] clikpopup://CCPS/reject16296No